The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...
The company said the single-arm multicenter Phase II trial may support accelerated approval for the RP-A501 gene therapy in the US.
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.
TORL BioTherapeutics' CLDN6-Targeting Antibody-Drug Conjugate Demonstrates Encouraging Early Results
Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ...
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...
The firm is testing azenosertib as a single agent and in combination with other drugs in various solid tumors and looking at response biomarkers.
The company recently discovered this gene signature in a large dataset of patients treated with a marketed a4β7 integrin antibody for ulcerative colitis.
Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.
The results, published in Nature, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line ...
A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback